Results 181 to 190 of about 125,716 (297)

The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. [PDF]

Pharmaceutics
Tornea DA, Goldis C, Isaic A, Motofelea AC, Sima AC, Ciocarlie T, Crintea A, Diaconescu RG, Motofelea N, Goldis A.   +9 more
europepmc   +1 more source

Metabolic Dysfunction-Associated Steatohepatitis With Positive Antimitochondrial M2 Antibodies: Diagnostic Pitfall and Importance of Follow-Up. [PDF]

Cureus
Mounsif S, Bahlaoui O, Delsa H, Khannoussi W, Ben El Barhdadi I.   +4 more
europepmc   +1 more source

Nonalcoholic Fatty Liver Disease: Evidence-Based Management and Early Recognition of Nonalcoholic Steatohepatitis [PDF]

, 2019
Nicole Kelly, Julia Wattacheril
openalex   +1 more source

Prevalence and Predictors of Hepatic Steatosis in Patients Undergoing Sleeve Gastrectomy: A Biopsy-proven Study. [PDF]

Obes Surg
Soliman R, Helmy A, Mikhail N, Ezzat H, Gad AM, Halim EA, Zalata K, Masoud R, Hassan A, Farahat A, Eisa MEEA, Elbasiony M, Shiha G.   +12 more
europepmc   +1 more source

Metabolische-Dysfunktion-assoziierte Steatotische Lebererkrankung und Metabolische-Dysfunktion-assoziierte Steatohepatitis: ein Update [PDF]

Eberhard Lurz, Christian Hudert, Daniel Weghuber, Elke Lainka   +3 more
openalex   +1 more source

Highly Reproducible, Vendor‐Agnostic, Motion‐Insensitive Liver PDFF Mapping at 0.55T, 1.5T, and 3T

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose To develop and validate a vendor‐agnostic, motion‐insensitive proton‐density fat‐fraction (PDFF) quantification method. Methods Flip‐angle‐modulated (FAM) 2D chemical‐shift‐encoded (CSE) MRI for PDFF quantification was implemented in both the vendor‐agnostic platform Pulseq (“Pulseq‐FAM”) and one vendor‐specific platform (“GE‐specific ...
Jiayi Tang, Daiki Tamada, Jon‐Fredrik Nielsen, Jitka Starekova, Julius F. Heidenreich, Felix Schön, Alexandra A. Anagnostopoulos, Amirhossein Roshanshad, Lu Mao, Shohei Fujita, Pengcheng Xu, Christopher Keen, Imam Ahmed Shaik, Eugene Milshteyn, Seonghwan Yee, Andrew J. Ellison, David Rutkowski, Jeff Kammerman, Jean H. Brittain, Xiaodong Zhong, William A. Grissom, Maxim Zaitsev, Aaron L. Carrel, Yogesh Rathi, Yun Jiang, Berkin Bilgic, Scott B. Reeder, Diego Hernando   +27 more
wiley   +1 more source

Retraction: Ammonia scavenger restores liver and muscle injury in a mouse model of non-alcoholic steatohepatitis with sarcopenic obesity. [PDF]

Front Nutr
Frontiers Editorial Office.
europepmc   +1 more source

Utilization of Noninvasive Tests to Diagnose At-Risk Metabolic Dysfunction-Associated Steatohepatitis. [PDF]

, 2023
Mazen Noureddin
openalex  

A Large-Scale Internal Validation Study of Unsupervised Virtual Trichrome Staining Technologies on Non-alcoholic Steatohepatitis Liver Biopsies [PDF]

, 2020
Joshua Levy, Nasim Azizgolshani, Michael J. Andersen, Arief A. Suriawinata, Xiaoying Liu, Mikhail Lisovsky, Bing Ren, Carly A. Bobak, Brock C. Christensen, Louis Vaickus   +9 more
openalex   +1 more source

Nanoformulated Diacerein Alleviates Hyperlipidemia via Gut Microbiota Modulation In Vivo

Nano Select, EarlyView.
A nanoformulation of diacerein (Nano‐DIA) was fabricated with carboxymethyl cellulose, achieving enhanced solubility and rapid dissolution for alternative anti‐hyperlipidemia therapeutics. Mechanistic studies revealed its in vivo lipid‐lowering efficacy is through metabolite‐mediated and microbiota‐dependent manner, highlighting its dual action on host
Zheng Peng, Yi Yu, Mingyi Chen, Weibin Wu, Chunyan Zhu, Caisheng Wu, Weihua Li, Zehua Liu, Qiang Xie   +8 more
wiley   +1 more source